$CGTX research team presented two posters at #AAIC2025 exploring the mechanism that underlies the impact of zervimesine in #Alzheimers disease. An analysis of cerebrospinal fluid (CSF) from Phase 2 'SHINE' participants who had lower levels of p-tau217 identified proteins that

$CGTX presented a poster at #AAIC2025 showing that #zervimesine treatment in the Phase 2 'SHINE' study arrested further cognitive deterioration in mild-to-moderate #Alzheimers patients who had lower levels of plasma p-tau217 regardless of their MMSE scores. Press Release:

$CGTX presented biomarker findings from the Phase 2 'SHINE' study of #zervimesine in #Alzheimers disease at #AAIC2025. In the prespecified subgroup of participants with lower levels of plasma p-tau217, significant reductions were observed in the level of plasma glial fibrillary

James Galvin of the @UMiamiCCBH presented results today at #AAIC2025 from the Phase 2 'SHIMMER' study of #zervimesine in #dementia with Lewy bodies. Read the full #pressrelease:

Read Benzinga's coverage of the $CGTX end-of-Phase 2 meeting that was conducted earlier in July with the #FDA to review #Alzheimers disease results to date and plans for a registrational program for #zervimesine: #Dementia #BiotechInnovation

$CGTX announced the publication of a proteomics analysis from the Phase 2 ‘SEQUEL’ COG0202 Study of zervimesine (CT1812) in adults with mild-to-moderate Alzheimer's disease. Read more in Alzheimer's & Dementia: Translational Research & Clinical Interventions here:

Yesterday $CGTX conducted an end-of-Phase 2 meeting with the #FDA to discuss plans for a Phase 3 program for #zervimesine as a treatment for #AlzheimersDisease. Read the press release: #Alzheimers #AlzheimersResearch #ClinicalTrials #BiotechInnovatoin

The Phase 2 ‘START’ Study has surpassed 50% enrollment. Read the $CGTX press release: The START Study is enrolling up to 540 people with #MCI and mild #Alzheimers who will be treated either with pbo or once-daily oral #zervimesine for 18mo. Learn more at

Read about the anonymous donation supporting $CGTX's expanded access program for people with #dementia with Lewy bodies on Benzinga: CEO Lisa Ricciardi credits investigators Drs. Galvin and Shprecher and their staff, who were instrumental in launching

Listen to the full #CognitionConversations podcast titled, “Studying the Patient-Caregiver Lived Experience in Dementia with Lewy Bodies” here: In this clip, Carla Preyer shares an example of how humor can play a role when dealing with difficult DLB

Mary Hamby, PhD and Britney Lizama, PhD recently presented posters at the Association for Research in Vision and Ophthalmology (ARVO)’s Annual Meeting #ARVO2025: Their presentations show that zervimesine may help regulate the uptake of lipids by retinal

$CGTX reported topline results today from a Phase 2 #clinicaltrial of zervimesine (CT1812) in #geographicatrophy (GA) secondary to #dryAMD. Read the press release here: Results: zervimesine-treated participants had 28.6% slower GA lesion growth. This

During #ADPD2025, Mary Hamby, PhD sat down with @marcomeglio1 from @neurology_live to discuss #zervimesine’s potential impact in #alzheimers treatment. Watch their full interview here: #Dementia #DementiaWithLewyBodies #BiotechInnovation #ClinicalResearch

CEO Lisa Ricciardi discuss with @benzinga the plan moving forward into Phase 3 trials having two indications, #dementia and #DementiaWithLewyBodies. Lisa’s full interview can be found here: #LewyBodyDementia #LBDAwareness #LewyStrong #BiotechInnovation

Thank you @marcomeglio1 and @neurology_live for the conversation at #ADPD2025.

Mary Hamby, PhD presented “Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients” at #ADPD2025. View Mary’s presentation: From biomarker discoveries to clinical

$CGTX CEO Lisa Ricciardi discusses with @DanLeachDTM of @Benzinga the plan to bring #zervimesine (CT1812) to market including the business development process currently in place. Watch Lisa’s full interview here: #LewyBodyDementia #dementia

$CGTX VP of research, Mary Hamby, PhD presented biomarker results from the Phase 2 SHINE study of zervimesine (CT1812) in mild-to-moderate #AlzheimersDisease at the #ADPD2025 Alzheimer’s & Parkinson’s Diseases Conference this morning. Read more about her presentation here: